Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Jasper Therapeutics Inc shares valued at $99,630 were purchased by WIGGANS THOMAS G on Sep 22 ’25. At $2.43 per share, WIGGANS THOMAS G acquired 41,000 shares. The insider’s holdings grew to 41,000 shares worth approximately $95530.0 following the completion of this transaction.
Also, Lucas Svetlana purchased 20,000 shares, netting a total of over 48,600 in proceeds. Following the buying of shares at $2.43 each, the insider now holds 20,000 shares.
Before that, MARTELL RON had added 41,000 shares to its account. In a trade valued at $99,630, the President and CEO bought Jasper Therapeutics Inc shares for $2.43 each. Upon closing the transaction, the insider’s holdings increased to 41,000 shares, worth approximately $0.17 million.
As published in a research note from RBC Capital Mkts on July 08, 2025, Jasper Therapeutics Inc [JSPR] has been rated down from an Outperform to a Sector perform and the price target has been revised to $5. Analysts at BMO Capital Markets downgraded the stock from ‘”an Outperform”‘ to ‘”a Market perform”‘ outlook in a report released in early July. As of July 07, 2025, William Blair has decreased its “an Outperform” rating to a “Mkt perform” for JSPR. Earlier on July 07, 2025, Cantor Fitzgerald downgraded its rating. Their new recommendation was “a Neutral” for JSPR stock which previously was a “an Overweight”.
Analyzing JSPR Stock Performance
The stock’s lowest price that day was $2.215, but it reached a high of $2.53 in the same session. During the last five days, there has been a drop of approximately -10.04%. Over the course of the year, Jasper Therapeutics Inc shares have dropped approximately -89.18%. Shares of the company reached a 52-week high of $22.52 on 01/02/25 and a 52-week low of $2.21 on 09/25/25.
Support And Resistance Levels for Jasper Therapeutics Inc (JSPR)
According to the 24-hour chart, there is a support level at 2.19, which, if violated, would cause prices to drop to 2.04. In the upper region, resistance lies at 2.50. The next price resistance is at 2.67. RSI (Relative Strength Index) is 35.15 on the 14-day chart, showing neutral technical sentiment.
Is Jasper Therapeutics Inc subject to short interest?
Stocks of Jasper Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -0.17 million shares to 1.12 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 1.29 million shares. A decline of -15.06% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.8 of the overall float, the days-to-cover ratio (short ratio) decline to 4.8.
Which companies own the most shares of Jasper Therapeutics Inc (JSPR)?
In terms of Jasper Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 55.5 in the next 12 months, up nearly 2281.97% from the previous closing price of $2.33. Analysts anticipate Jasper Therapeutics Inc stock to reach 65 by 2025, with the lowest price target being 3. In spite of this, 7 analysts ranked Jasper Therapeutics Inc stock as Buy at the end of 2025. On February 13, 2025, UBS assigned a price target of “a Buy” to the stock and initiated coverage with a $38.
